Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Catalyst Pharmaceuticals (CPRX) Net Margin (2018 - 2025)

Historic Net Margin for Catalyst Pharmaceuticals (CPRX) over the last 11 years, with Q3 2025 value amounting to 35.57%.

  • Catalyst Pharmaceuticals' Net Margin rose 14700.0% to 35.57% in Q3 2025 from the same period last year, while for Sep 2025 it was 37.54%, marking a year-over-year increase of 91100.0%. This contributed to the annual value of 33.23% for FY2024, which is 182800.0% up from last year.
  • Per Catalyst Pharmaceuticals' latest filing, its Net Margin stood at 35.57% for Q3 2025, which was up 14700.0% from 35.55% recorded in Q2 2025.
  • Catalyst Pharmaceuticals' Net Margin's 5-year high stood at 41.92% during Q4 2022, with a 5-year trough of 29.96% in Q3 2023.
  • Its 5-year average for Net Margin is 29.98%, with a median of 34.1% in 2024.
  • As far as peak fluctuations go, Catalyst Pharmaceuticals' Net Margin tumbled by -1191000bps in 2021, and later soared by 640600bps in 2024.
  • Over the past 5 years, Catalyst Pharmaceuticals' Net Margin (Quarter) stood at 24.3% in 2021, then soared by 73bps to 41.92% in 2022, then tumbled by -50bps to 20.77% in 2023, then soared by 88bps to 39.09% in 2024, then decreased by -9bps to 35.57% in 2025.
  • Its Net Margin stands at 35.57% for Q3 2025, versus 35.55% for Q2 2025 and 40.12% for Q1 2025.